Pharsight

Spiriva Respimat patents expiration

SPIRIVA RESPIMAT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7988001

(Pediatric)

BOEHRINGER INGELHEIM Container provided with a pressure equalization opening
Feb, 2022

(1 year, 7 months ago)

US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(10 months from now)

US7284474

(Pediatric)

BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Feb, 2025

(1 year, 4 months from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(1 year, 7 months from now)

US7896264

(Pediatric)

BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
Nov, 2025

(2 years from now)

US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Oct, 2026

(3 years from now)

US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2027

(3 years from now)

US7396341

(Pediatric)

BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Apr, 2027

(3 years from now)

US9027967

(Pediatric)

BOEHRINGER INGELHEIM Device for clamping a fluidic component
Oct, 2027

(4 years from now)

US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2028

(4 years from now)

US7837235

(Pediatric)

BOEHRINGER INGELHEIM Device for clamping a fluidic component
Sep, 2028

(4 years from now)

US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Oct, 2030

(7 years from now)

US8733341

(Pediatric)

BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Apr, 2031

(7 years from now)

Spiriva Respimat is owned by Boehringer Ingelheim.

Spiriva Respimat contains Tiotropium Bromide.

Spiriva Respimat has a total of 13 drug patents out of which 1 drug patent has expired.

Expired drug patents of Spiriva Respimat are:

  • US7988001*PED

Spiriva Respimat was authorised for market use on 24 September, 2014.

Spiriva Respimat is available in spray, metered;inhalation dosage forms.

The generics of Spiriva Respimat are possible to be released after 16 April, 2031.

Drugs and Companies using TIOTROPIUM BROMIDE ingredient

Market Authorisation Date: 24 September, 2014

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

How can I launch a generic of SPIRIVA RESPIMAT before it's drug patent expiration?
More Information on Dosage

SPIRIVA RESPIMAT family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic